Business & Regulation

It's Trump or Clinton for President. But what are the implications for pharma?

Costs of failing to communicate can cost you collaboration and investment.

Have Mylan been their own worst enemy with an imprudent pricing decision?

Emma Walmsley is chosen as GlaxoSmithKline's new CEO.

Richard Bergstrom has resigned from EFPIA - who will replace him?

Critics say a report from the UN on access to medicines ignores the real word industry

Our infographic looks at how the CPhI trade show has grown over the years.

Not all successful biosimilar applications in Europe follow guidelines to the letter

Why is the pharma industry so despised when it has saved countless lives?

Mylan introduces new schemes to help tackle EpiPen costs for patients, as well as plans for a new direct-to-patient distribution model